title: HMR-3562. Aventis Pharma.
abstract: Aventis Pharma (formerly Hoechst Marion Roussel) is investigating the ketolides HMR-3562 and HMR-3787 as potential antibacterial agents. The compounds belong to a series of 2-fluoroketolides. They have exhibited potency against a range of gram-positive bacteria and other respiratory tract pathogens including Haemophilus influenzae in vitro and in vivo.
authors.affiliation: Infectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064-3537, USA. zhenkun.ma@abbott.com
authors.forename: Z
authors.initials: Z
authors.lastname: Ma
authors.forename: A S
authors.initials: AS
authors.lastname: Florjancic
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D018942:Macrolides; D013329:Structure-Activity Relationship
chemical_list: D000900:Anti-Bacterial Agents; C438106:HMR 3562; D018942:Macrolides